Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638547 · ClinicalTrials.gov registry record · Phase 1
Intrathecal Enzyme Replacement for Hurler Syndrome
A Phase 1 study of Hurler Syndrome, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00638547 is a Phase 1 study of Hurler Syndrome that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00638547, a Phase 1 study of Hurler Syndrome, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoing transplantation.
Conditions Studied
Interventions
- DRUG IRT Laronidase
Study Locations (1)
Minnesota
- University of Minnesota, Fairview - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-01-02 |
| Est. Completion | 2018-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638547
The ClinicalTrials.gov registry entry for NCT00638547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hurler Syndrome appearing as the primary indexed condition, and to 1 intervention - of which IRT Laronidase is the first listed.
NCT00638547 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00638547 about?
NCT00638547 is a clinical study titled "Intrathecal Enzyme Replacement for Hurler Syndrome". This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoi...
What is the current status of trial NCT00638547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-01-02. Estimated completion is 2018-11-18.
What conditions does trial NCT00638547 study?
This clinical trial studies the following conditions: Hurler Syndrome.
What interventions are being tested in trial NCT00638547?
The interventions under investigation include: IRT Laronidase (DRUG).
Who is sponsoring clinical trial NCT00638547?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00638547 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hurler Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.